SGMO News and Press, Sangamo Therapeutics Inc.

Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process Sangamo has secured c...

2026-06-23 06:06:30 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow Sangamo Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings C...

RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company’s pipeline and financial resources, it has retained Raymond James as its financial adv...

2026-06-01 10:15:37 ET Oncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnol...

AUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced deli...

2026-05-26 12:15:03 ET H.C. Wainwright analyst issues BUY recommendation for SGMO on May 26, 2026 03:12PM ET. The previous analyst recommendation was Buy. SGMO was trading at $0.2091 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Curren...

2026-05-14 18:31:29 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript ...

2026-05-14 18:30:45 ET Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

2026-05-14 16:25:30 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript Sangamo Therapeutics Q1 2026 Earnings Preview Sangamo targets summ...

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain. Held productive interaction with U.K. Medicines and Health...